Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
Natalia J GuruleKenneth C MalcolmChelsea HarrisJennifer R KnappBrian P O'ConnorJazalle McClendonWilliam J JanssenFrank Fang Yao LeeCaitlin PriceJackson Osaghae-NosaEmily A WheelerChristine M McMahonEric M PietrasDaniel A PollyeaScott AlperPublished in: Leukemia (2023)
Myelodysplastic neoplasm (MDS) is a hematopoietic stem cell disorder that may evolve into acute myeloid leukemia. Fatal infection is among the most common cause of death in MDS patients, likely due to myeloid cell cytopenia and dysfunction in these patients. Mutations in genes that encode components of the spliceosome represent the most common class of somatically acquired mutations in MDS patients. To determine the molecular underpinnings of the host defense defects in MDS patients, we investigated the MDS-associated spliceosome mutation U2AF1-S34F using a transgenic mouse model that expresses this mutant gene. We found that U2AF1-S34F causes a profound host defense defect in these mice, likely by inducing a significant neutrophil chemotaxis defect. Studies in human neutrophils suggest that this effect of U2AF1-S34F likely extends to MDS patients as well. RNA-seq analysis suggests that the expression of multiple genes that mediate cell migration are affected by this spliceosome mutation and therefore are likely drivers of this neutrophil dysfunction.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- ejection fraction
- newly diagnosed
- chronic kidney disease
- mouse model
- prognostic factors
- atrial fibrillation
- gene expression
- type diabetes
- genome wide
- cell migration
- single cell
- dna methylation
- high resolution
- autism spectrum disorder
- intellectual disability
- patient reported
- acute lymphoblastic leukemia
- wild type
- genome wide analysis